LGL Partners LLC Purchases Shares of 11,308 VanEck Biotech ETF $BBH

LGL Partners LLC acquired a new stake in shares of VanEck Biotech ETF (NASDAQ:BBH – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,308 shares of the company’s stock, valued at approximately $2,298,000. VanEck Biotech ETF accounts for 0.9% of LGL Partners LLC’s investment portfolio, making the stock its 17th largest holding. LGL Partners LLC owned approximately 0.58% of VanEck Biotech ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Kestra Advisory Services LLC grew its stake in shares of VanEck Biotech ETF by 3.0% in the 1st quarter. Kestra Advisory Services LLC now owns 3,405 shares of the company’s stock valued at $640,000 after buying an additional 98 shares during the period. Janney Montgomery Scott LLC grew its stake in VanEck Biotech ETF by 3.4% in the first quarter. Janney Montgomery Scott LLC now owns 3,040 shares of the company’s stock valued at $572,000 after acquiring an additional 100 shares during the period. Wealthfront Advisers LLC lifted its holdings in shares of VanEck Biotech ETF by 2.3% in the 4th quarter. Wealthfront Advisers LLC now owns 5,513 shares of the company’s stock worth $1,043,000 after purchasing an additional 122 shares in the last quarter. Evelyn Partners Asset Management Ltd grew its position in VanEck Biotech ETF by 16.9% in the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock valued at $178,000 after purchasing an additional 136 shares during the period. Finally, Empowered Funds LLC acquired a new stake in VanEck Biotech ETF in the 4th quarter valued at $38,000. Institutional investors own 32.05% of the company’s stock.

Get VanEck Biotech ETF alerts:

VanEck Biotech ETF Stock Performance

BBH opened at $235.50 on Tuesday. VanEck Biotech ETF has a fifty-two week low of $160.91 and a fifty-two week high of $244.35. The company’s 50-day moving average is $213.87 and its 200 day moving average is $197.38.

Insider Buying and Selling

In other VanEck Biotech ETF news, major shareholder Sardar Biglari sold 2,749 shares of the firm’s stock in a transaction on Thursday, July 16th. The stock was sold at an average price of $16.70, for a total transaction of $45,908.30. Following the transaction, the insider directly owned 3,549,961 shares in the company, valued at approximately $59,284,348.70. This trade represents a 0.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 10,493 shares of company stock valued at $175,335.

VanEck Biotech ETF Profile

(Free Report)

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.

Featured Stories

• Five stocks we like better than VanEck Biotech ETF
• Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
• Insiders Are Betting Big on These 3 Healthcare Stocks
• 3 Stocks for Investors Who Still Believe Cash Is King
• Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.